TRIPLE-1/FUJITSU
18.3.2019 16:02:06 CET | Business Wire | Press release
TRIPLE-1, Inc. (Representative Director: Takuya Yamaguchi) and Fujitsu Electronics Inc. (Representative Director: Junji Ogihara) have entered into a distributorship contract for a mining ASIC (application specific IC) “KAMIKAZE” that uses the world's most advanced 7nm process technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005034/en/
--- Background:
In the development market for mining ICs, which requires huge computing power and high power efficiency, the introduction of advanced process technology has been attempted positively and just like the development market for ICs for smartphones, which is one of the world's leading manufacture industries, the driving force for development came from the process miniaturization in the advanced semiconductor industry. As of 2019, there is a mover away from the mainstream 16nm process which had been the oligopoly of traditional Chinese region manufacturers to the state-of-the-art 7nm process. In the past, several companies, including Japanese companies, announced their entry into cutting-edge 7nm process development, but at the moment there are only a handful of manufacturers that have succeeded in commercializing ASIC (application specific IC).
--- Purpose / Perspective:
TRIPLE-1 is a semiconductor system development company established in
November 2016 and specializing in cutting-edge process technology.
Since
February 2017, we began to develop the ASIC (application specific IC)
"KAMIKAZE" for bitcoin mining adopting the world's most advanced 7nm
process technology.
About a year later in February 2018, we
announced the world's first tape-out (design completion) in the
state-of-the-art 7nm process for the same application and proceeded with
commercialization by TSMC (Taiwan), the world's largest foundry.
Currently
TRIPLE-1 is the only manufacturer of ASIC (application specific IC) that
adopts the state-of-the-art 7nm process technology in Japan and is the
only Japanese company that confronts the world in the cutting-edge
process development market.
Fujitsu Electronics develops a wide
range of products from various brands and manufacturers for markets
around the world by making full use of the global network spreading both
in Japan and abroad, centered on the "Fujitsu brand" that has continued
to be trusted for many years around the world.
Through the signing
of this distributorship contract, we will be able to spread the global
development potential of Fujitsu Electronics and the state-of-the-art
process development capabilities of TRIPLE-1 all over the world and
provide the real value of “Japanese manufacturing” to markets around the
world. On top of that, by establishing a long-term and strong
partnership, we will cooperate not only in mining ASIC (application
specific IC), but also in the development and deployment of leading-edge
products for various fields and applications.
--- TRIPLE-1 “KAMIKAZE” Product Features:
1. Adopts the world's most advanced 7nm process technology
Develops
the world's first "KAMIKAZE", an ASIC (application specific IC) for
bitcoin mining with using world's Leading-Edge company TSMC (Taiwan) ’s
7nm process technology and evaluates the first tape out (first
generation) version, Power Efficiency: 52 J / TH was realized (measured
on September 26, 2018).
2. Reduced energy consumption that contributes to energy resource
conservation
By operating at ultra-low voltage (0.3V or less)
and achieving low power consumption, it is possible to contribute to the
reduction of the enormous power required for mining and energy resource
conservation while maintaining a high performance.
3. High cooling efficiency from changes in packaging
In
order to achieve higher cooling efficiency, we adopted a structure
(exposed die - FCBGA) in which the backside of the silicon chip is
exposed on the package to achieve higher cooling efficiency, chip size
was encapsulated in 7 mm × 7 mm.
--- TRIPLE-1 outline:
Company Name: TRIPLE-1, Inc.
Corporate Headquarter:
7F IT
Bldg.Ⅱ,1-14-20 Hakataeki-Higashi, Hakata-ku Fukuoka-shi, Fukuoka, Japan
Representatives:
Representative Director CEO Takuya Yamaguchi
The capital: 3662
million 895 thousand and 398 yen (including the capital reserve)
--- Features of Fujitsu Electronics:
As an "Electronics General Trading Company" that contributes to the development of customers' businesses through offering an extensive lineup of Fujitsu brand products centered on LSIs with leading-edge technology and proprietary products, as well as domestic and overseas manufacturer products, with comprehensive support including sales, technology, solution services, logistic services and more. With 13 locations in Japan and 20 locations overseas, we have established a global distributor system that can propose a wide range of solutions, building a consistent network that can respond to customer requests in a timely manner, from product procurement to development and mass production.
--- Fujitsu Electronics outline:
Company Name: Fujitsu Electronics Inc.
Corporate Headquarter:
2-100-45,
Shin-Yokohama, Kohoku-Ku, Yokohama-shi, Kanagawa, Japan
Representatives:
President and Representative Director Junji Ogihara
The capital:
4,877,683,581 yen
Website: http://www.fujitsu.com/jp/fei/en/
--- About the trademark:
Proper nouns such as the product names listed are trademarks or registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190318005034/en/
Contact:
Regarding this Press Release: TRIPLE-1, Inc. Public Relations Office GAKU MATSUSHIMA info@triple-1.com
Regarding Sales and Products: Fujitsu Electronics Inc. fei-triple1@dl.jp.fujitsu.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
